Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
January 13, 2021
Virtual Bayer Pharma Media Day:

Bayer transforms pharma business through breakthrough innovation in healthcare

READ MORE
January 12, 2021

U.S. FDA grants Priority Review to New Drug Application for finerenone

READ MORE
January 7, 2021

Bayer issues new senior bonds with a volume of 4 billion euros

READ MORE
January 7, 2021

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

Read more
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
71 - 80of about 600 News
71 - 80of about 600 News
January 31, 2020
Bayer Welcomes U.S. Environmental Protection Agency’s Reaffirmation that Glyphosate Is Safe to Use, Not Carcinogenic
READ MORE
January 31, 2020
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
READ MORE
January 30, 2020
Not intended for U.S. and UK Media – Updated results of Phase III trial show:
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
READ MORE
January 23, 2020
Not intended for U.S. and UK Media
Bayer receives approval for darolutamide in Japan
READ MORE
January 13, 2020
Not intended for U.S. and UK Media
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
READ MORE
December 10, 2019
Bayer to significantly step-up its sustainability efforts
READ MORE
December 10, 2019
Bayer to significantly step-up its sustainability efforts
READ MORE
November 29, 2019
Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
READ MORE
November 25, 2019
Not intended for U.S. and UK Media
Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism
READ MORE
November 18, 2019
Not intended for U.S. and UK Media
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint
READ MORE
71 - 80of about 600 News
71 - 80of about 600 News